Home About us Contact
|
Home About us Contact | ||
|
|
||
Toxin Treatment (toxin + treatment)
Kinds of Toxin Treatment Selected AbstractsBotulinum-A Toxin Treatment of the Lower Eyelid Improves Infraorbital Rhytides and Widens the EyeDERMATOLOGIC SURGERY, Issue 8 2001Timothy Corcoran Flynn MD Botulinum-A exotoxin (BTX-A) can be used cosmetically to improve rhytides, particularly of the upper one-third of the face. In this study, fifteen women had BTX-A (BOTOX, Allergan, Inc.) injected into the orbicularis oculi muscle. One lower eyelid received two units just subdermally in the midpupillary line three millimeters below the ciliary margin. The opposite periocular area received two units BTX-A in the lower eyelid with 12 units BTX-A injected into the lateral orbital ("crow's foot") area. Three injections of four units each were placed 1.5 cm from the lateral canthus, each 1 cm apart. Patients and physicians independently evaluated the degree of improvement (grade 0 = no improvement, grade 1 = mild improvement, grade 2 = moderate improvement, and grade 3 = dramatic improvement). An independent photographic analysis was performed. Patients reported a grade of 0.73 when two units were injected alone into the lower lid, and a grade of 1.9 when the lower eyelid and the lateral orbital areas were injected. Physician assessment was grade 0.7 with injection of the eyelid alone and grade 1.8 with injection of the lower eyelid and lateral orbital area. Single investigator photographic analysis demonstrated that 40% of the subjects who had injection of the lower eyelid alone had an increased palpebral aperture (IPA), while 86% of the subjects who had injection of the lower eyelid and lateral orbital area had an IPA. Subjects receiving two units alone had an average 0.5 mm IPA and a mean 1.3 mm IPA at full smile. Concomitant treatment of the lateral orbital area produced a mean 1.8 mm IPA at rest and a mean 2.9 mm IPA at full smile. The results were more notable in the Asian eye. Two units of BTX-A injected into the lower eyelid orbicularis oculi muscle improves infraorbital wrinkles, particularly when used in combination with BTX-A treatment of the lateral orbital area. [source] Effects of Fusaric Acid on Reactive Oxygen Species and Antioxidants in Tomato Cell CulturesJOURNAL OF PHYTOPATHOLOGY, Issue 10 2001E. Ku Generation of O2, and H2O2 as well as the activities of superoxide dismutase, catalase, ascorbate peroxidase, guaiacol peroxidase, dehydroascorbate reductase and ascorbate content were studied in tomato cell cultures in response to fusaric acid , a nonspecific toxin of phytopathogenic Fusarium species. Toxin treatment resulted in decreased cell viability which was preceded by culture medium alkalinization up to 0.65 pH unit and enhanced extracellular O2, production. The H2O2 level was not significantly affected. In toxin-treated cultures, a transient, significant increase occurred in intracellular superoxide dismutase, catalase, guaiacol peroxidase and ascorbate peroxidase activities. Fusaric acid-induced ascorbate turnover modulation led to up to a twofold increase in dehydroascorbic acid accumulation, and a decrease in the associated ascorbate redox ratio. It was concomitant with a significant decrease in dehydroascorbate reductase activity. These results support previous observations that the pro- and anti-oxidant systems are involved in response to fusaric acid treatment although differential response of H2O2 and its metabolism-related enzymes between the whole leaf and cell culture assays was found. [source] Patient-Reported Outcomes with Botulinum Toxin Type A Treatment of Glabellar Rhytids: A Double-Blind, Randomized, Placebo-Controlled StudyDERMATOLOGIC SURGERY, Issue 2007FACS, STEVEN FAGIEN MD BACKGROUND Global patient-reported outcomes do not evaluate specific aspects of treatment that are important to patients. OBJECTIVE The objective was to evaluate self-perception of age and specific outcomes that are important to patients receiving botulinum toxin type A or placebo for moderate to severe glabellar lines (using the Facial Line Outcomes Questionnaire to assess how much facial lines bother them, make them look older, detract from their facial appearance, prevent a smooth facial appearance, and make them look tired, stressed, or angry). METHODS AND MATERIALS In the double-blind phase of this 12-week study, 70 patients were randomly assigned to treatment with 20 U botulinum toxin type A (BOTOX Cosmetic) or placebo. At Week 4, those still with moderate or severe glabellar lines were offered open-label 20 U botulinum toxin type A. RESULTS Median glabellar line severity was significantly lower after botulinum toxin treatment than after placebo. Compared with placebo, botulinum toxin also resulted in significantly superior patient assessments and a greater proportion of patients considering they looked younger than their current age. CONCLUSIONS Botulinum toxin type A can achieve specific goals of treatment that are important to patients and help them feel that they look younger than their current age. [source] Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystoniaMOVEMENT DISORDERS, Issue 16 2007Richard Walsh MB Abstract Disorganization of sensory cortical somatotopy has been described in adult onset primary torsion dystonia (AOPTD). Although botulinum toxin type A (BTX-A) acts peripherally, some studies have suggested a central effect. Our primary hypothesis was that sensory cortical reorganization occurs after BTX-A treatment of AOPTD. Twenty patients with cervical dystonia and 18 healthy age-matched control patients had spatial discrimination thresholds (SDTs) measured at baseline and monthly for 3 months. Mean baseline SDT (±SD) was 1.75 ±0.76 mm in the dystonia group, greater than the control group mean of 1.323 ± 0.45 mm (P = 0.05). Mean control group SDT did not vary significantly over time. A transient improvement of 23% from baseline (P = 0.005) occurred in the dystonia group 1 month after injection, which did not positively correlate with changes in physician and patient ratings of torticollis severity. The presumed mechanism of SDT improvement is a modulation of afferent cortical inputs from muscle spindles. © 2007 Movement Disorder Society [source] Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitisMOVEMENT DISORDERS, Issue 9 2006Nina Browner MD Abstract Patients with Rasmussen encephalitis (RE) may develop a variety of involuntary movements. We report a 26-year-old woman who presented with a 3-year history of progressive, continuous myoclonus of the left side of the face and left arm as well as left spastic hemiparesis. Magnetic resonance imaging of the brain showed right hemisphere and basal ganglia atrophy, and 24-hour electroencephalogram demonstrated diffuse slowing with random sharp waves in both hemispheres. An 18-fluoro-deoxy-glucose positron emission tomography scan indicated hypometabolism of the right cerebral hemisphere, including basal ganglia and thalamus. We successfully treated her myoclonus with injections of botulinum toxin A into the left zygomaticus muscle. © 2006 Movement Disorder Society [source] Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxinMOVEMENT DISORDERS, Issue S8 2004Frank J. Erbguth MD Abstract Food-borne botulism probably has accompanied mankind since its beginning. However, we have only few historical sources and documents on food poisoning before the 19th century. Some ancient dietary laws and taboos may reflect some knowledge about the life-threatening consumption of poisoned food. One example of such a dietary taboo is the 10th century edict of Emperor Leo VI of Byzantium in which manufacturing of blood sausages was forbidden. Some ancient case reports on intoxications with Atropa belladonna probably described patients with food-borne botulism, because the combination of dilated pupils and fatal muscle paralysis cannot be attributed to an atropine intoxication. At the end of the 18th century, some well-documented outbreaks of "sausage poisoning" in Southern Germany, especially in Württemberg, prompted early systematic botulinum toxin research. The German poet and district medical officer Justinus Kerner (1786,1862) published the first accurate and complete descriptions of the symptoms of food-borne botulism between 1817 and 1822. Kerner did not succeed in defining the suspected "biological poison" which he called "sausage poison" or "fatty poison." However, he developed the idea of a possible therapeutic use of the toxin. Eighty years after Kerner's work, in 1895, a botulism outbreak after a funeral dinner with smoked ham in the small Belgian village of Ellezelles led to the discovery of the pathogen Clostridium botulinum by Emile Pierre van Ermengem, Professor of bacteriology at the University of Ghent. The bacterium was so called because of its pathological association with the sausages (Latin word for sausage = "botulus") and not,as it was suggested,because of its shape. Modern botulinum toxin treatment was pioneered by Alan B. Scott and Edward J. Schantz. © 2004 Movement Disorder Society [source] Inhibition of photosynthesis and modification of the wheat leaf proteome by Ptr ToxB: A host-specific toxin from the fungal pathogen Pyrenophora tritici-repentisPROTEINS: STRUCTURE, FUNCTION AND BIOINFORMATICS, Issue 16 2010Yong Min Kim Abstract Tan spot, caused by Pyrenophora tritici-repentis, is an important foliar disease of wheat. The fungus produces the host-specific, chlorosis-inducing toxin Ptr ToxB. To better understand toxin action, we examined the effects of Ptr ToxB on sensitive wheat. Photosynthesis, as measured by infrared gas analysis, declined significantly within 12,h of toxin treatment, prior to the development of chlorosis at 48,72,h. Analysis by 2-DE revealed a total of 102 protein spots with significantly altered intensities 12,36,h after toxin treatment, of which 66 were more abundant and 36 were less abundant than in the buffer-treated control. The identities of 47 of these spots were established by MS/MS, and included proteins involved in the light reactions of photosynthesis, the Calvin cycle, and the stress/defense response. Based on the declines in photosynthesis and the identities of the differentially abundant proteins, we hypothesize that Ptr ToxB causes a rapid disruption in the photosynthetic processes of sensitive wheat, leading to the generation of ROS and oxidative stress. Although the photoprotective and repair mechanisms of the host appear to initially still be functional, they are probably overwhelmed by the continued production of ROS, leading to chlorophyll photooxidation and the development of chlorosis. [source] Dynamic behaviour and localization of pseudoglottis in alaryngeal voice related to voice qualityCLINICAL OTOLARYNGOLOGY, Issue 4 2000A.J.G.E. Peeters Objective. To evaluate the pseudoglottic position and dynamic behaviour of alaryngeal voice after laryngectomy related to voice quality. Patients and methods. Pseudoglottic vibrations during sustained phonation were evaluated by videofluoroscopy, videostroboscopy and videokymography in 15 laryngectomees and related to perceptual voice quality, assessed by two independent speech therapists. Videokymography can be used to identify irregular vibrations. This combined with videofluoroscopy and videostroboscopy characterizes the dynamic behaviour of the pseudoglottis. Results. Videofluoroscopy and videostroboscopy demonstrated a mid-neopharyngeal pseudoglottis in 10 laryngectomees, five of whom had an additional inferior located pseudoglottis. Four patients only had a pseudoglottis localized low in the neopharynx and one patient had no pseudoglottis at all. Videokymographic evaluation of pseudoglottic vibrations could be obtained in eight patients, surprisingly demonstrating a regular vibration pattern in all cases. Good alaryngeal voice quality was related to a mid-neopharyngeal pseudoglottis. This is consistent with our experience concerning botulinum toxin treatment for neopharyngeal hypertonicity (injection in the low pseudoglottis reduced phonatory pressure and increased voice quality, whereas injection in the mid-neopharyngeal pseudoglottis resulted in voice deterioration). Conclusion. Good alaryngeal voice quality is related to a mid-neopharyngeal pseudoglottis which should be taken into consideration when treating hypertonicity. [source] Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugateFEBS JOURNAL, Issue 18 2007Sandra E. Geden Saporin is a type I ribosome-inactivating protein that is often appended with a cell-binding domain to specifically target and kill cancer cells. Urokinase plasminogen activator (uPA)-saporin, for example, is an anticancer toxin that consists of a chemical conjugate between the human uPA and native saporin. Both saporin and uPA-saporin enter the target cell by endocytosis and must then escape the endomembrane system to reach the cytosolic ribosomes. The latter process may represent a rate-limiting step for intoxication and would therefore directly affect toxin potency. In the present study, we document two treatments (shock with dimethylsulfoxide and lipopolyamine coadministration) that generate substantial cellular sensitization to saporin/uPA-saporin. With the use of lysosome-endosome X (LEX)1 and LEX2 mutant cell lines, an endosomal trafficking step preceding cargo delivery to the late endosomes was identified as a major site for the dimethylsulfoxide-facilitated entry of saporin into the cytosol. Dimethylsulfoxide and lipopolyamines are known to disrupt the integrity of endosome membranes, so these reagents could facilitate the rapid movement of toxin from permeabilized endosomes to the cytosol. However, the same pattern of toxin sensitization was not observed for dimethylsulfoxide- or lipopolyamine-treated cells exposed to diphtheria toxin, ricin, or the catalytic A chain of ricin. The sensitization effects were thus specific for saporin, suggesting a novel mechanism of saporin translocation by endosome disruption. Lipopolyamines have been developed as in vivo gene therapy vectors; thus, lipopolyamine coadministration with uPA-saporin or other saporin conjugates could represent a new approach for anticancer toxin treatments. [source] | |||||||||||||